The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo

Veterinary Journal

Volumn 198, Issue 3, 2013, Pages 577-582

  Ito, Keita ^a   Kobayashi, Masato ^a   Kuroki, Shiori ^a   Sasaki, Yu ^a   Iwata, Taisuke ^a   Mori, Kohei ^a   Kuroki, Tetsuya ^a   Ozawa, Yuta ^a   Tetsuka, Masanori ^a   Nakagawa, Tomoko ^a   Hiroi, Teruyo ^a   Yamamoto, Hitomi ^a   Ono, Kenichiro ^a,b   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b Japan Animal Referral Medical Center   (Japan)

Author keywords

Bortezomib; Dog; Melanoma; NF B

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

CANIS FAMILIARIS;

BORTEZOMIB; DOG; MELANOMA; NF-ΚB;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOG DISEASES; DOGS; MELANOMA; NF-KAPPA B; PROTEASOME INHIBITORS; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 84888439044     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.08.003     Document Type: Article

References (37)

1. An J., Sun Y., Fisher M., Rettig M.B. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004, 18:1699-1704.
2. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A.E., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 2003, 9:1284-1290.
3. Bollag G., Tsai J., Zhang J., Zhang C., Ibrahim P., Nolop K., Hirth P. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery 2012, 11:873-886.
4. Brockley L.K., Cooper M.A., Bennett P.F. Malignant melanoma in 63 dogs (2001-2011): The effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal 2012, 61:25-31.
5. Carvajal R.D., Antonescu C.R., Wolchok J.D., Chapman P.B., Roman R.A., Teitcher J., Panageas K.S., Busam K.J., Chmielowski B., Lutzky J., et al. KIT as a therapeutic target in metastatic melanoma. Journal of the American Medical Association 2011, 305:2327-2334.
6. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 2011, 364:2507-2516.
7. Chu P.Y., Pan S.L., Liu C.H., Lee J., Yeh L.S., Liao A.T. KIT gene exon 11 mutations in canine malignant melanoma. The Veterinary Journal 2013, 192:226-230.
8. Colado E., Alvarez-Fernández S., Maiso P., Martín-Sánchez J., Vidriales M.B., Garayoa M., Ocio E.M., Montero J.C., Pandiella A., San Miguel J.F. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008, 93:57-66.
9. Coquelle A., Mouhamad S., Pequignot M.O., Braun T., Carvalho G., Vivet S., Métivier D., Castedo M., Kroemer G. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death and Differentiation 2006, 13:873-875.
10. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. Journal of Clinical Oncology 2006, 24:4340-4346.
11. Dank G., Rassnick K.M., Sokolovsky Y., Garrett L.D., Post G.S., Kitchell B.E., Sellon R.K., Kleiter M., Northrup N., Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Veterinary and Comparative Oncology 2013, 10.1111/j.1476-5829.2012.00338.x.
12. Fennell D.A., Chacko A., Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008, 27:1189-1197.
13. Freeman K.P., Hahn K.A., Harris F.D., King G.K. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). Journal of Veterinary Internal Medicine 2003, 17:96-101.
14. Guo J., Si L., Kong Y., Flaherty K.T., Xu X., Zhu Y., Corless C.L., Li L., Li H., Sheng X., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of Clinical Oncology 2011, 29:2904-2909.
15. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
16. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research 2001, 61:3071-3076.
17. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008, 22:985-988.
18. Isotani M., Yamada O., Lachowicz J.L., Tamura K., Yagihara H., Fujino Y., Ono K., Washizu T., Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. British Journal of Haematology 2010, 148:144-153.
19. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: A treasure trove for drug development. Nature Reviews Drug Discovery 2004, 3:17-26.
20. Keefe D.M., Bateman E.H. Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology 2011, 9:98-109.
21. Kojima K., Fujino Y., Goto-Koshino Y., Ohno K., Tsujimoto H. Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines. Journal of Veterinary Medical Science 2013, 75:727-731.
22. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., Neuberg D., Goloubeva O., Pien C.S., Adams J., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research 2002, 62:4996-5000.
23. Lioni M., Noma K., Snyder A., Klein-Szanto A., Diehl J.A., Rustgi A.K., Herlyn M., Smalley K.S. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics 2008, 7:2866-2875.
24. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
25. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates 2008, 11:164-179.
26. Murakami A., Mori T., Sakai H., Murakami M., Yanai T., Hoshino Y., Maruo K. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Veterinary and Comparative Oncology 2011, 9:219-224.
27. Murphy S., Hayes A.M., Blackwood L., Maglennon G., Pattinson H., Sparkes A.H. Oral malignant melanoma - The effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Veterinary and Comparative Oncology 2005, 3:222-229.
28. Pérez-Galán P., Mora-Jensen H., Weniger M.A., Shaffer A.L., Rizzatti E.G., Chapman C.M., Mo C.C., Stennett L.S., Rader C., Liu P., Raghavachari N., et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011, 117:542-552.
29. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of Immunology 2003, 171:88-95.
30. Proulx D.R., Ruslander D.M., Dodge R.K., Hauck M.L., Williams L.E., Horn B., Price G.S., Thrall D.E. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary Radiology and Ultrasound 2003, 44:352-359.
31. Qin J.Z., Xin H., Sitailo L.A., Denning M.F., Nickoloff B.J. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Research 2006, 66:9636-9645.
32. Rassnick K.M., Ruslander D.M., Cotter S.M., Al-Sarraf R., Bruyette D.S., Gamblin R.M., Meleo K.A., Moore A.S. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). Journal of the American Veterinary Medical Association 2001, 218:1444-1448.
33. Reece D.E., Sullivan D., Lonial S., Mohrbacher A.F., Chatta G., Shustik C., Burris H., Venkatakrishnan K., Neuwirth R., Riordan W.J., et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology 2011, 67:57-67.
34. Shelly S., Chien M.B., Yip B., Kent M.S., Theon A.P., McCallan J.L., London C.A. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mammalian Genome 2005, 16:211-217.
35. Smith S.H., Goldschmidt M.H., McManus P.M. A comparative review of melanocytic neoplasms. Veterinary Pathology 2002, 39:651-678.
36. Williamson M.J., Silva M.D., Terkelsen J., Robertson R., Yu L., Xia C., Hatsis P., Bannerman B., Babcock T., Cao Y., et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Molecular Cancer Therapeutics 2009, 8:3234-3243.
37. Woodman S.E., Trent J.C., Stemke-Hale K., Lazar A.J., Pricl S., Pavan G.M., Fermeglia M., Gopal Y.N., Yang D., Podoloff D.A., et al. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics 2009, 8:2079-2085.